Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment by Caporali, R, Aletaha, D, Sanmarti, R, Takeuchi, T, Mo, D, Haladyj, E, Zaremba-Pechmann, L, Taylor, PC

Descriptive study of patients with uveitis attended during one-year period - diagnostic classification and treatment by Cañete J D, Adan A, Espinosa G, Ramirez J, Gomez-Puerta J A, Ruiz-Esquide V, Hernández M V, Sanmarti R

Synovial fibroblast hyperplasia correlates with rheumatoid arthritis duration and activity and is partially reversed by anti-TNF therapy by Pablos J L, Criado G, Sanmartí R, Marsal S, Usategui A, Del Rey M J, Celis R, Cañete J D, Izquierdo E

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study by Caporali, R, Taylor, PC, Aletaha, D, Sanmartí, R, Takeuchi, T, Mo, D, Haladyj, E, Bello, N, Zaremba-Pechmann, L, Fang, Y, Dougados, M

Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis by Sanmarti R, Alsina M, Blanco F, Rodriguez R, Moll C, Montilla C, Suarez B, Lopez R, Fernadez-Sueiro J L, Ramirez J, Lozano F, Cañete J